Radiologists see potential to reduce GBCA administration with new synthetic MRI technique

Neuroradiologists have shown it is now possible to assess cancer patients’ response to treatment without administering gadolinium-based contrast agents, according to new data. Some experts believe it may help radiologists reduce their reliance on GBCAs.

With the help of deep learning, German researchers generated synthetic post-contrast T1-weighted MRI sequences using pre-contrast sequences, they reported Thursday in The Lancet Digital Health.

GBCA-free scans showed no significant difference when used to assess glioblastoma patients’ response to treatment compared to images enhanced with contrast. With further testing, the group sees their approach as a blueprint for radiologists to reduce the specialty’s use of contrast materials. 

“These results suggest that although contrast-enhancing tumor volumes are underestimated when using synthetic post-contrast T1-weighted sequences, quantification of the relative change in the longitudinal tumor burden resembles the information that would otherwise only be available with administration of GBCA and acquisition of true post-contrast T1-weighted sequences,” Chandrakanth Jayachandran Preetha, MsC, with Heidelberg University Hospital’s Department of Neuroradiology, and co-authors added.

For their retrospective study, the team trained and validated their network on more than 5,000 MRI scans with further independent testing completed using another 1,900 exams.

Preetha et al. found mean time to progression was similar using GBCA-based and synthetic images, but the latter did classify 15% of patients with tumor progression who weren't classified as such based on contrast-enhanced scans.

In an accompanying editorial, two Dutch radiology experts pointed out the technique was validated on trial data from patients treated across 200 institutions, suggesting it can generalize across MRI machines.

“Such a performance suggests that synthetic samples could act as a meaningful substitute for GBCA-based images in determining treatment effects (in a trial setting), even if not being perfect copies that are readily recognized by human observers,” Alexandros Ferles, PhD, and Frederik Barkhof, MD, PhD, both with Amsterdam University Medical Center’s Department of Radiology and Nuclear Medicine, added. “Whether they perform equally well in a diagnostic setting was not examined.”

 

Related MRI Contrast Agent Safety Content:

A deep dive into gadolinium-based adverse reactions

Allergic reactions to iodinated CT contrast increase likelihood of sensitivity to GBCAs

Researchers detail data on gadolinium-related adverse reactions

Radiologists must take a data-driven approach to discuss gadolinium, mitigate liability risk

Radiologists see potential to reduce GBCA administration with new synthetic MRI technique

Gadolinium-based contrast agents are safe, even at higher doses, new research suggests

Gadolinium debate rages on, with radiologist questioning recent GBCA liability guidance

ACR committee proposes new term for symptoms associated with gadolinium exposure

Closing the knowledge gap on gadolinium retention risks

Radiologists find direct evidence linking gadolinium-based contrast agent to higher retention rates

AI software that eliminates need for gadolinium contrast during imaging exams wins patent

Research may offer new method to detect GBCA on MRI

Radiology, other multispecialty groups urge caution with GBCAs during interventional pain procedures

Cardiac MRI contrast agents are low-risk and safe for ‘overwhelming’ majority of patients

Health orgs publish special report about gadolinium retention, GBCA use in imaging

Rodent brains retain gadolinium after repeated administration of GBCA a year after injection

Advanced MRI mapping spots traces of gadolinium in the brain invisible during conventional scanning

Radiologists should keep patients’ best interests in mind to mitigate gadolinium liability risk

Gadolinium Risk Management: 3 Pillars for a Sound Strategy

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.